RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising drug cocktail targets tough blood cancers in kids
Disease control Recruiting nowThis study tests whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control relapsed or treatment-resistant T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LLy) in patients aged 1 month to 21 years. T…
Matched conditions: RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cell therapy offers hope for tough blood cancers
Disease control Recruiting nowThis study tests a new treatment called CTD402 for people with T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) that has come back or not responded to other treatments. Participants receive one infusion of CTD402 and are monitored for safety and how w…
Matched conditions: RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BIOHENG THERAPEUTICS US LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Engineered immune cells take on tough T-Cell cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called BEAM-201 for children and young adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments. BEAM-201 uses donor-derived immune cells that are engin…
Matched conditions: RELAPSED/REFRACTORY T-CELL LYMPHOBLASTIC LYMPHOMA
Phase: PHASE1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC